R
Reliant Immune Diagnostics
Testing, diagnosing and monitoring solutions
About Reliant Immune Diagnostics
Reliant ID is at the forefront of the telehealth revolution, providing an integrated patient-driven health platform that simplifies access to healthcare. The company serves a diverse range of clients including employers, retailers, healthcare platforms, long-term care facilities, and individual patients. Operating in the telehealth market, Reliant ID leverages advanced technology to offer comprehensive medical care, testing, diagnosing, and monitoring solutions. The business model is centered around providing cost-effective, on-demand healthcare services without compromising on patient care. Revenue is generated through service fees from various stakeholders in the healthcare ecosystem, including subscription models for employers and healthcare platforms, and pay-per-use fees for individual patients. The company prides itself on its experienced team of engineers, healthcare professionals, designers, and innovators who are united by a mission to improve healthcare for everyone. By offering greater access to healthcare and lowering costs, Reliant ID aims to make healthcare more inclusive and efficient.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Austin, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reliant Immune Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reliant Immune Diagnostics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

